dr. K. (Kevin) Damman

Kevin Damman is clinical heart failure cardiologist and medical director of the heart transplant and left ventricular assist device division and coronary care unit at the University Medical Center Groningen. His research focuses on acute and advanced heart failure, with particular emphasis on the cardiorenal axis. Current research interests are focused on improving treatment of acute heart failure patients, including early assessment of effect of decongestive therapies, SGLT2-inhibition in (acute) heart failure and the role of the kidney in the process of cardiorenal interaction. He was (co)principle investigator of the PUSH-AHF and EMPA-RESPONSE-AHF studies on improving diuretic response in acute heart failure, and was part of the ADVOR steering committee. Currently he is principle investigator of the mechanistic COMPARE-VS study on vicadrostat vs spironolactone in cardiorenal patients, part of the steering committee of the FASTR randomized controlled trial with the Reprieve decongestive system, the DAPA-RHT study on dapagliflozin post heart transplantation and the EMPA-AHF trial empagliflozin in acute heart failure patients in Japan. He is a fellow of the Heart Failure Assocation of the ESC and Chair of the Advanced HF committee of the HFA.